These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35203982)

  • 21. [Comorbid states in Parkinson's disease: an effect of MAO-B inhibitors].
    Titova NV; Katunina EA; Sotnikova NN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(4):90-99. PubMed ID: 27386592
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson's disease: a multiple treatment comparison meta-analysis.
    Binde CD; Tvete IF; Gåsemyr JI; Natvig B; Klemp M
    Eur J Clin Pharmacol; 2020 Dec; 76(12):1731-1743. PubMed ID: 32710141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson's disease.
    Viallet F; Pitel S; Lancrenon S; Blin O
    Curr Med Res Opin; 2013 Jan; 29(1):23-31. PubMed ID: 23176073
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson's Disease with Neuroprotective Potential.
    Finberg JP
    Rambam Maimonides Med J; 2010 Jul; 1(1):e0003. PubMed ID: 23908775
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impulse Control and Related Disorders in Parkinson's Disease.
    Weintraub D; Claassen DO
    Int Rev Neurobiol; 2017; 133():679-717. PubMed ID: 28802938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selegiline ameliorates depression-like behaviors in rodents and modulates hippocampal dopaminergic transmission and synaptic plasticity.
    Ishikawa T; Okano M; Minami A; Tsunekawa H; Satoyoshi H; Tsukamoto Y; Takahata K; Muraoka S
    Behav Brain Res; 2019 Feb; 359():353-361. PubMed ID: 30359642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rasagiline, an inhibitor of MAO-B, decreases colonic motility through elevating colonic dopamine content.
    Liu CZ; Zhang XL; Zhou L; Wang T; Quan ZS; Zhang Y; Li J; Li GW; Zheng LF; Li LS; Zhu JX
    Neurogastroenterol Motil; 2018 Nov; 30(11):e13390. PubMed ID: 29956417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours.
    Finberg JP; Youdim MB
    Neuropharmacology; 2002 Dec; 43(7):1110-8. PubMed ID: 12504917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study.
    Masellis M; Collinson S; Freeman N; Tampakeras M; Levy J; Tchelet A; Eyal E; Berkovich E; Eliaz RE; Abler V; Grossman I; Fitzer-Attas C; Tiwari A; Hayden MR; Kennedy JL; Lang AE; Knight J;
    Brain; 2016 Jul; 139(Pt 7):2050-62. PubMed ID: 27190009
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects.
    Schapira AH
    CNS Drugs; 2011 Dec; 25(12):1061-71. PubMed ID: 22133327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selegiline Recovers Synaptic Plasticity in the Medial Prefrontal Cortex and Improves Corresponding Depression-Like Behavior in a Mouse Model of Parkinson's Disease.
    Okano M; Takahata K; Sugimoto J; Muraoka S
    Front Behav Neurosci; 2019; 13():176. PubMed ID: 31427934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rasagiline in treatment of Parkinson's disease.
    Nayak L; Henchcliffe C
    Neuropsychiatr Dis Treat; 2008 Feb; 4(1):23-32. PubMed ID: 18728823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of rasagiline in the treatment of Parkinson's disease.
    Leegwater-Kim J; Bortan E
    Clin Interv Aging; 2010 May; 5():149-56. PubMed ID: 20517484
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease.
    Chen JJ; Ly AV
    Am J Health Syst Pharm; 2006 May; 63(10):915-28. PubMed ID: 16675649
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful use of rasagiline in combination with two antidepressants: a case report.
    Kaur N; Madan R; Sharma A
    Innov Clin Neurosci; 2012 Nov; 9(11-12):39-41. PubMed ID: 23346517
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rasagiline induced hypersexuality in Parkinson's disease.
    Reyes D; Kurako K; Galvez-Jimenez N
    J Clin Neurosci; 2014 Mar; 21(3):507-8. PubMed ID: 24055209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Case Report on Serotonin Syndrome in a Patient With Parkinson's Disease: Diagnostic and Management Challenges.
    Nemet M; Andrijević A; Nedeljkov Đ; Andrić V; Gavrilović S
    Cureus; 2023 Mar; 15(3):e36780. PubMed ID: 37123809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease.
    Hauser RA; Silver D; Choudhry A; Eyal E; Isaacson S;
    Mov Disord; 2014 Jul; 29(8):1028-34. PubMed ID: 24919813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.